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KEY POINTS
 Invasive candidiasis and mold infections are a common cause of hospital-acquired infections often related to the use of invasive lines, immunosuppression, and a contaminated
environment.
 Traditional culture methodologies may be insensitive for the diagnosis of fungal infections
and may require the use of more sensitive nonculture-based testing.
 The control and prevention of invasive fungal infections require a combination of traditional infection control practices, as well as the use of antifungal prophylaxis in high-risk
individuals.
 There has been an increase in the rates of invasive fungal infection during the COVID-19
pandemic as a result of gaps in infection control practices and use of immunosuppression
for treatment of COVID-19 infection.

IMPACT OF NOSOCOMIAL FUNGAL INFECTIONS

There has been an overall increase in fungal health care–associated infections (HAIs).
The increase is partly due to the increased population of immunocompromised patients at risk for invasive fungal infection as a consequence of the wider use of treatment modalities, such as hematopoietic stem cell transplantation (HSCT), solid organ
transplantation (SOT), and newer immunomodulatory agents (Table 1).1–3 Moreover,
the increasing use of invasive devices, especially central venous catheters (CVCs),
has resulted in an increase in nosocomial central line-associated bloodstream infections (CLABSIs) due to Candida spp.1,3,4 Exposure to airborne molds such as Aspergillus spp. within the hospital environment has caused outbreaks of nosocomial
aspergillosis in severely immunocompromised patients such as allogeneic HSCT recipients and neutropenic patients with hematologic malignancies.5
a
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Candida

Aspergillus

Mucorales

Fusarium

Scedosporium

 Acute necrotizing pancreatitis
 Abdominal surgery; anastomotic
leak; or repeat laparotomies
 Broad-spectrum antibiotics
 Central venous catheters
 Hemodialysis
 HSCT
 Immunosuppression including
corticosteroids, chemotherapy
 Malignancy
 Mechanical ventilation >3 d
 Multifocal candida colonization
 Neutropenia
 Prolonged ICU stay
 Prolonged hospitalization
 SOT (kidney and liver)
 Total parenteral nutrition

 Alemtuzumab
 Allogeneic HSCT
 Anastomotic complications
in lung transplantation
 Aspergillus colonization
 CMV disease
 Corticosteroids
 Infliximab
 Neutropenia
 Older age
 Prolonged ICU stay
 Renal failure requiring dialysis
 Retransplantation
 Severe GVHD
 T-cell depleting agents














 Corticosteroid
 Myeloma
 Severe GVHD

 Corticosteroid
 Neutropenia
 Severe GVHD

CMV disease
Corticosteroids
Diabetes mellitus
Echinocandin use
Iron overload
Malnutrition
Myelodysplasia
Neutropenia
Older age
Renal failure
Severe GVHD
Voriconazole use

Abbreviations: CMV, cytomegalovirus; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; IA, intraabdominal; ICU, intensive care
unit; SOT, solid organ transplantation.
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Table 1
Risk factors associated with invasive fungal infections

Nosocomial Fungal Infections

Candida spp. are associated with serious HAIs, especially in patients in intensive
care units (ICUs)1,3,4,6 and are one of the most common causes of nosocomial bloodstream infections (BSIs) in US hospitals.3,4 It is estimated that approximately 25,000
cases of invasive candidiasis (IC) occur in the United States each year.7,8 The true incidence of candidemia is likely higher because of the poor sensitivity (approximately
50%) of blood cultures (BCs) for detection of Candida spp. Newer automated rapid
nonculture-based test (NCT) molecular platforms have improved the diagnostic yield
in patients with IC.3 Candida auris, an emerging multidrug-resistant species that is
difficult to identify, has been associated with nosocomial outbreaks and IC globally
and in the United States.7 The attributable mortality for IC, including candidemia, is
significant, and the excess health care cost ranges from $35,000 to $68,000 for
each episode of candidemia in the United States.3,9
The incidence rate of invasive aspergillosis (IA) per million persons rose from 32.8 in
2000 to 46.0 in 2013, especially in SOT recipients.10 Aspergillosis accounted for 59%
of all invasive fungal infections and was associated with a 6-week mortality rate of
22% in severely immunocompromised patients.11,12
Thus, the overall burden of disease caused by nosocomial fungal infections is substantial. Limitations of the current diagnostic tests, the emergence of resistant fungal
pathogens, and significant mortality make the prevention of fungal HAIs increasingly
important. The epidemiology, risk factors associated with nosocomial fungal infections, and control and prevention strategies are discussed in the following
paragraphs.13–15
COMMON NOSOCOMIAL INFECTIONS CAUSED BY YEASTS
Candida spp.

Candida spp., especially Candida albicans, are part of the human microbial flora;
hence, most candidal infections are endogenous in origin. IC, namely, candidemia,
disseminated hematogenous infections, or deep-seated infections can occur in
immunocompromised patients, such as those with neutropenia, and in critically ill
patients. In patients with chemotherapy-induced neutropenia and mucositis, candidemia may originate from the gastrointestinal tract. However, in critically ill patients,
the source of candidemia is most likely a CVC colonized by Candida spp. from the
patient’s endogenous microflora or acquired from the health care environment.1,3
Candida spp. have been isolated from environmental cultures of the floor, countertops, and other inanimate surfaces in the hospital.16,17 Patient acquisition and colonization with Candida spp. found in the hospital environment and food has been
demonstrated.8,16 The propensity of Candida spp., especially Candida parapsilosis,
to cause CLABSIs is likely related to this pathogen’s ability to form biofilms on
catheters.18
Overall, Candida spp. accounted for 6.4% of 356,633 HAIs reported to the National
Healthcare Safety Network (NHSN) at the Centers for Disease Control and Prevention
(CDC) between 2015 and 2017.4 Approximately, 11% of infections in North American
ICUs were due to Candida spp.19 Notably, Candida spp. were the most common
cause of CLABSIs in the ICU and hospital wards, accounting for 25% and 16.7% of
CLABSIs, respectively.4 The increasing proportion of patients with candidemia in nonICU settings is possibly due to the presence of long-term CVCs.3 Additional risk factors for nosocomial candidemia are listed in Table 1. Candidemia-related
hospitalization per 100,000 population rose by 52%, from 3.65 to 5.56 cases between
2000 and 2005.20 However, from 2009 to 2017, the change in incidence of IC-related
hospitalizations remained low at 1.3%.21
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A study of IC from 203 centers in the United States between 2009 and 2017 identified C
albicans (48%), Candida glabrata (24%), C parapsilosis (11%), and C tropicalis (7%) as the
most common Candida pathogens.21,22 The overall 90-day crude mortality rate associated with candidemia was 39%. Overall, there has been an increase in the proportion
of infections caused by nonalbicans Candida spp.22,23 In the United States, nonalbicans
Candida spp. were reported to cause most candidemias.22 Most of the nonalbicans species, particularly C glabrata, are reported from cancer centers in the United States.22 In
contrast, higher rates of C parapsilosis and C tropicalis are reported from Latin America.24
Nonalbicans Candida spp. have an increased likelihood of resistance to fluconazole: 16%
of C glabrata, 78% of Candida krusei, and 11% of C guilliermondii.24
Although most cases of IC are endogenous, exogenous transmission of Candida
spp. may occur. Characteristics of specific Candida spp. may influence the risk for
exogenous transmission and nosocomial infections in certain patient populations.
In molecular epidemiologic studies, C albicans has been implicated in nosocomial
transmission among patients in burn units.25 Person-to-person transmission has
also been reported from geriatric short-stay units.26
C parapsilosis candidemia is common in the neonatal population18,22 and transplant
recipients.18 C parapsilosis is commonly isolated from the hands of health care
workers (HCWs), and a review of molecular epidemiologic studies of outbreaks suggests horizontal transmission from HCWs to neonates.18 The ability of C parapsilosis
to produce biofilms and its selective growth advantage in glucose-rich hyperalimentation solutions in total parenteral nutrition (TPN) may explain its propensity to cause
outbreaks associated with CVCs.18 Hence, the frequent isolation of C parapsilosis
should prompt measures to enhance hand hygiene and appropriate care of CVCs.
Emerging Candida spp. that are relatively resistant to fluconazole such as C auris,8
C guilliermondii,27 and Candida rugosa28 have also been associated with nosocomial
outbreaks, some involving CVCs. C auris first isolated from the external ear canal of a
hospitalized patient in Japan in 2009 has since been associated with nosocomial outbreaks in health care facilities globally.8,29 Its ability to persistently colonize patients
and survive on surfaces for months has contributed to outbreaks.8,29–32
The first C auris case in the United States was identified in New York in 2013.30 As of
March 19, 2021, there have been 1708 confirmed clinical cases in the United States,
most of which have occurred in New York City, New Jersey, and Chicago, Illinois.8
More recently, an outbreak was reported in patients with coronaviorus disease 2019
(COVID-19) who received care in a dedicated COVID-19 unit.31 Infection and colonization have been detected mainly in critically ill patients with comorbidities and exposure to healthcare facility (HCF). Risk factors for C auris are similar as those for other
Candida infections and include prolonged ICU stay, recent surgery, antibiotic and antifungal use, CVCs or indwelling urinary catheters, TPN, hematological malignancies,
SOT, HSCT, and immunosuppression.30,32
C auris has been misidentified as C haemulonii when using conventional diagnostic
methods.8,29,30,32 It has been cultured from blood, urine, bile, wounds, and rectum.8,30,32
Most of the reported C auris cases are BSIs, but pericarditis, otitis, and wound infections
can occur.30,32 C auris is often resistant to one or more classes of antifungal agents.31–33
Of 35 isolates in the United States, 86% were resistant to fluconazole, 43% to amphotericin B, and 3% to echinocandins,29 which is the drug of choice in clinical infections.8,29
Despite geographic variability, overall mortality rates range from 35% to 72%.32
Other Yeasts

Malassezia spp. are lipophilic yeasts that are frequent skin colonizers and the cause of
pityriasis. Outbreaks of Malassezia fungemia have been reported in premature
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neonates and immunocompromised patients.34,35 Prolonged use of CVCs and TPN
were important predisposing conditions.34,35
Trichosporon spp. fungemia has been reported in patients with hematologic malignancies and HSCT and SOT recipients.36 Systemic disease has also been reported in
premature neonates, diabetics, nonneutropenic ICU, and burn patients.36,37 Common
risk factors in cases of nosocomial trichosporonosis are the presence of a CVC and
exposure to prior antibiotics.37 Waterborne outbreaks have also been reported.38
The reported mortality rate ranges from 42% to 83%.36,37
Most outbreaks of nosocomial IC and invasive infections with other yeasts have been
associated with CVCs. Hence, infection control strategies targeted to improve adherence to hand hygiene recommendations, including avoidance of long nails and artificial
nails, adherence to guidelines for insertion and care of CVCs, and prompt removal of
unnecessary catheters are important in the prevention of these infections.39
NOSOCOMIAL INFECTIONS CAUSED BY MOLDS

Unlike IC, which can affect relatively immunocompetent patients, invasive disease
caused by Aspergillus spp. and other molds generally involves severely immunocompromised patients. Aspergillus spp. account for most mold infections: 76% among
HSCT recipients and 81% among SOT recipients.1 Although several outbreaks of environmental airborne fungal infection within hospital settings have been reported,5 most
cases of IA are sporadic. At present, there is no uniform definition of what constitutes
nosocomial aspergillosis. One of the primary reasons for the difficulty in defining
hospital-acquired aspergillosis is that the incubation period of IA is unknown.2 Moreover, the prolonged period of immunosuppression in high-risk patients such as HSCT
recipients and frequent hospital admissions and discharges make it difficult to determine if exposure to Aspergillus spores occurred during hospitalization or within the
community. Generally, invasive disease that occurs after 1 week of hospitalization is
considered nosocomial.2 Although most hospital outbreaks have been caused by
Aspergillus spp.,5 other airborne molds have also been implicated, including Zygomycetes spp.,5,40 Fusarium spp.,5 and Scedosporium spp.5,41 The risks factors for mold
infections and vehicles of transmission are summarized in Table 1 and Table 2.
Table 2
Reported vehicles of transmission in invasive mold infections and associated types of
infections
Mold

Reservoir or Source

Type of Infection

Aspergillus

Contaminated air, ventilation system,
air filters, false ceilings and insulation
material, water supply, plumbing,
showers, food, ornamental plants,
arm boards, dressing package

Invasive pulmonary and
disseminated aspergillosis,
cutaneous disease

Mucorales

Contaminated air, Elastoplast adhesive
dressing, karaya ostomy bag, wooden
tongue depressor, ventilation systems,
water-damaged plaster, cornstarch,
linens

Cutaneous infections,
sinopulmonary disease,
gastrointestinal mucormycosis

Fusarium

Contaminated air, contact lens solution,
showers, sink drains and faucets,
water tanks

Keratitis, disseminated fusariosis

Scedosporium

Contaminated air

Pulmonary and disseminated
disease, cutaneous lesions
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Aspergillus spp.

Aspergillus spp. are ubiquitous molds found widely in the environment. Exposure to
airborne spores of Aspergillus occurs frequently in the environment, especially near
decaying organic matter. Although these conidia (2.5–3.0 mm in diameter) are
frequently inhaled, invasive pulmonary disease is rare in immunocompetent persons.
Opportunistic IA occurs primarily in high-risk severely immunocompromised patients
namely allogeneic HSCT and neutropenic patients with hematologic malignancies.
Aspergillus fumigatus is most often associated with invasive disease, although Aspergillus flavus, Aspergillus niger, and Aspergillus terreus have also been isolated from
patients.1,42 Aspergillosis is an important cause of morbidity and mortality ranging
from 65% to 92% in this high-risk population.2,43
SOT recipients,2,44 patients with acquired immunodeficiency syndrome (AIDS), and
those with chronic granulomatous disease are also at risk for IA.2 There are increasing
reports of IA in critically ill patients in the ICU, including patients with chronic obstructive pulmonary disease, severe influenza, COVID-19, liver cirrhosis, and those
receiving corticosteroids.2,45–47
Aspergillus outbreaks

The information on the environmental exposures and the association with infection
has been derived from investigations of outbreaks of aspergillosis in hospital settings. An extensive review of nosocomial aspergillosis identified 53 reported outbreaks involving 458 patients.48 Of these, 33 outbreaks involving 299 patients
(65%) occurred in HSCT recipients or patients with hematologic malignancies. Other
patient populations involved in these outbreaks were SOT recipients (10%), predominately renal transplant recipients; patients without severe immunodeficiency (8%);
and patients on high-dose steroids (3%).48 Aspergillosis was associated with mortality greater than 50% in patients with hematologic malignancies, HSCT and SOT recipients, and patients with severe immunodeficiency. The lung was the most
common site of infection, with 5% involving the surgical site or skin. A fumigatus
and A flavus were the most identified species. Volumetric air sampling performed
during epidemiologic investigations in 24 of the outbreaks noted spore counts
ranging from 0 to 100 spores per cubic meter. Outbreaks were primarily attributed
to airborne infections related to construction or renovation activities in about 50%
of cases and to compromised air quality in 17%.48 The various environmental vehicles implicated in the transmission of Aspergillus spp. and other molds have also
been detailed in the CDC guidelines for environmental infection control in HCFs
(see Table 2).14
The most frequent nosocomial source of Aspergillus infection is contaminated air,
but Aspergillus has also been recovered from the hospital water supply and plumbing
systems.2,38 The highest airborne Aspergillus spore counts were detected in patient’s
bathrooms, suggesting possible aerosolization of Aspergillus spores from the shower
facilities.2 The clinical implications of this finding remain to be defined.
Although the association between construction and IA has often been reported,
there is poor correlation of the Aspergillus spp. recovered from the hospital environment and species isolated from patients with aspergillosis.2 One explanation for this
discordance between hospital and patient strains of Aspergillus might relate to the
lack of a clearly defined incubation period for aspergillosis and the relationship to
exposure within the hospital environment and subsequent infection.2 Other factors
include the methods of air sampling used, the broad diversity of Aspergillus spp. in
the environment, and the various methods used for typing of Aspergillus and other
pathogenic molds.49,50
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Zygomycetes

Zygomycetes are ubiquitous molds found in the soil and decaying organic matter in
the environment. Infection often occurs via inhalation of fungal spores, resulting in
sinopulmonary disease, but systemic infection can result from inoculation of the
skin or gastrointestinal mucosa.51 Although infection caused by Zygomycetes is uncommon, it is often a fatal disease. In a review of 929 patients with zygomycosis, mortality was 76% with pulmonary zygomycosis and 100% with disseminated and central
nervous system diseases.52
Nosocomial infections caused by Zygomycetes have been recently reviewed.40
Clusters of cutaneous infections have occurred in orthopedic and cardiothoracic patients, children with leukemia, and burn patients. These infections were associated
with Elastoplast adhesive dressings possibly contaminated with Rhizopus and Absidia
spp.40 Outbreaks in patients with hematologic malignancies have resulted from
airborne transmission associated with contamination of hospital ventilation systems.5
Use of negative pressure rooms during construction has also been implicated in a
cluster of invasive mucormycosis infection among SOT recipients during a 12-month
period.53 Water-damaged plaster has been associated with Rhizomucor pusillius
outbreak in patients with leukemia.40 Unusual routes of transmission have been traced
to the use of contaminated wooden tongue depressors, nonsterile karaya (plantderived adhesive) for securing ostomy bags, and wooden tongue depressors.40 An
outbreak of gastrointestinal zygomycosis caused by Rhizopus in 12 patients with hematologic malignancies was traced to contaminated cornstarch used as an excipient
in the manufacture of allopurinol and ready-to-eat foods.54 Additionally, hospital linens
have also been implicated in outbreaks.55
Fusarium spp.

Fusarium is a soil saprophyte and causes keratitis and onychomycosis in humans.56
Outbreaks of keratitis caused by possible contamination of contact lens solutions
have been described.56,57 Invasive disease has been reported in patients with prolonged neutropenia, especially in HSCT recipients56,58 and to a lesser extent in
SOT recipients.56 The incidence of fusariosis is estimated to be 4 to 5 cases per
1000 matched allogeneic HSCT recipients to as high as 20 cases per 1000 mismatched recipients.59 Fusariosis in HSCT recipients has a bimodal distribution,
with a peak before engraftment and later during the period of graft-versus-host disease (GVHD), and is associated with an actuarial survival of 13%.58 Most infections
are believed to be caused by airborne transmission; however, contamination of the
water system in the hospital has been reported to result in dispersal of airborne
conidia.38
Other Molds

Several other pathogenic molds have been associated with HAIs. Nosocomial outbreaks caused by Scedosporium spp. during hospital reconstruction have been reported.60 Phialemonium spp. have been linked to outbreaks of intravascular
infections in patients undergoing hemodialysis (HD), resulting from contamination
of water distribution systems.61 A multistate outbreak of fungal meningitis, parameningeal, and joint infections occurred in 753 patients who received injections of
contaminated methylprednisone acetate solutions, resulting in 64 (8.5%) deaths
across 20 states. The predominant pathogen detected in this outbreak was
Exserophilum.62
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Pneumocystis jiroveci

Opportunistic pneumonia caused by Pneumocystis jirovecii has been traditionally
attributed to reactivation of latent infection during periods of severe T-cell–mediated
immunosuppression, particularly in transplant recipients and patients with AIDS. However, recent data suggest possible person-to-person transmission or common environmental source as a potential mode of transmission.63 Molecular evidence has
also identified nosocomial person-to-person transmission of Pneumocystis jiroveci
to be the likely cause of outbreaks of Pneumocystis pneumonia, particularly among
renal transplant recipients.63 In a meta-analysis of 30 outbreaks, more than 80%
occurred among renal transplant recipients. None of the patients received appropriate
antipneumocystis prophylaxis.
STRATEGIES FOR PREVENTION OF NOSOCOMIAL CANDIDIASIS
Prevention of Intravascular Catheter-Related Candidemia

Guidelines for the prevention of CLABSI have been published.13 Although randomized
clinical trials have shown that daily 2% chlorhexidine gluconate (CHG) bathing of patients in the ICU decreases the incidence of nosocomial multidrug-resistant bacterial
BSIs, few studies have evaluated the impact on candidemia.64,65 A meta-analysis of
five randomized controlled trials evaluating the efficacy of CHG bathing in reducing
BSIs showed that CHG had no effect on fungal BSIs.65 However, a more recent
meta-analysis of 26 randomized and nonrandomized studies demonstrated that
CHG bathing was associated with a significant reduction in BSIs, including those
due to Candida spp.64 A multicenter, randomized, crossover study also found that
the incidence of fungal CLABSIs was 90% lower during the CHG intervention period
compared with the control period.66 Despite the conflicting results, use of daily
CHG bathing in patients in the ICU is a simple and effective strategy to decrease
the overall rate of primary BSIs.
Additionally, the use of disinfection caps, which include alcohol or alcohol/CHG
combinations, placed on needleless connectors or access ports has demonstrated
decreased CLABSI rates.67,68
Unlike other Candida spp., C auris can spread rapidly in HCFs and lead to nosocomial outbreaks that can be difficult to contain. Patients can remain colonized even after a year, leading to environmental shedding where it can survive and persist on a
wide range of surfaces.32 A single case of C auris requires rapid implementation of
infection control measures and investigation. When C auris is suspected or confirmed,
the patient should be placed in a single room under contact precautions with reinforcement of hand hygiene practices. Additional infection prevention and control measures include daily and terminal cleaning and disinfection of patient care areas using
an Environmental Protection Agency–registered hospital-grade disinfectant effective
against Clostridioides difficile spores, contact tracing and testing, prospective laboratory surveillance to identify other potential cases for at least 1 month until there is no
evidence of ongoing transmission, and interfacility communication during patient
transfer.8,29
STRATEGIES FOR PREVENTION OF NOSOCOMIAL ASPERGILLOSIS AND MOLD
INFECTIONS

Aspergillosis is primarily acquired by inhalation of fungal spores and subsequent
invasive disease in immunocompromised patients. Hence, the primary infection control strategy is to minimize exposure to airborne environmental fungal spores within
HCFs during the high-risk period. Exposure to fungal spores of Aspergillus spp. and
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS
North America) from ClinicalKey.com/nursing by Elsevier on February 14, 2022. For personal use
only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

Nosocomial Fungal Infections

other pathogenic molds after hospital discharge may occur in high-risk patients,
such as allogeneic HSCT recipients with chronic GVHD who are administered corticosteroids. Patient education to minimize exposures to fungal spores and chemoprophylaxis with antifungal agents may be necessary. Guidelines for the use of
antifungal agents for prophylaxis against IA have been previously published15 and
updated.2
The CDC and Healthcare Infection Control Practices Advisory Committee have published recommendations regarding environmental infection control measures to prevent nosocomial mold infections in HCFs.14 These recommendations include
infection control strategies and engineering controls directed primarily for the prevention of exposure of immunocompromised patients to environmental airborne fungal
spores of Aspergillus and other molds.14
Because opportunistic Aspergillus and airborne mold infections occur primarily in
severely immunocompromised patients such as HSCT recipients; one of the main
components of these prevention strategies is the provision of a protected environment
(PE) for these patients within the HCF.
Protected Environment

A PE is a specialized patient care environment in acute care hospitals for the care of
allogeneic HSCT recipients.13,14 The benefit of a PE for other immunocompromised
patients such as autologous HSCT or SOT recipients remains undefined.14,60 A PE
is designed to minimize HSCT patient exposure to airborne environmental Aspergillus
and other fungal spores. The essential features of a PE are shown in Box 1. Additional
infection control measures for patients housed in a PE include (1) daily monitoring and
maintenance of a positive pressure in PE areas, (2) minimizing exposures to activities
that can cause aerosolization of fungal spores (eg, vacuuming), (3) minimizing the
length of time that the patients are outside the PE for procedures, and (4) provision
of high-efficiency respiratory protection (eg, N95 respirators) when outside the PE if
there is ongoing construction activity in the HCF.14 The effectiveness of respirators
in the absence of construction or the use of surgical masks to prevent fungal infection
has not been evaluated.
The other infection control strategies and engineering control recommendations
that reduce exposure to environmental airborne Aspergillus and other fungal spores
emphasize the provision of safe air during routine care and importantly during hospital
construction.14 These strategies are outlined in Table 3.

Box 1
Protective environment
Requirements of protective environment rooms
 Central or point-of-use high-efficiency particulate air (HEPA) filters with 99.97% efficiency
for removing particles 0.3 mm or larger
 Directed airflow, air intake occurs at 1 side and air exhaust occurs at the opposite side of the
room
 Positive air pressure differential between the room and corridor (2.5 Pa)
 Maintenance of 12 or more air changes per hour
 Well-sealed patient rooms
Data from Sehulster L, Chinn RY. Guidelines for environmental infection control in health-care
facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory
Committee (HICPAC). MMWR Recomm Rep 2003;52(RR–10):1–42.
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Table 3
Environmental infection control measures in healthcare facilities to minimize exposure to
fungal spores
Recommendations

Rating Category

Air handling systems
Use the American Institute of Architects (AIA) guidelines or state
regulations for design and construction of ventilations systems164

1C

Conduct ICRA and provide adequate number of PE rooms for the
HSCT population

1A, 1C

Monitor ventilation systems for removal of particulates and excess
moisture
Proper location and maintenance of air intake and exhaust outlets,
for example, removal of bird roosts from near air intake outlets
to prevent entry of fungal spores
Appropriate installation, maintenance, and disposal of HVAC
filters
Monitor PE areas for ACH, filtration, and pressure differentials

1B, 1C

Develop a contingency plan for backup capacity in case of a power
failure

1C

Coordinate HVAC system shutdowns with infection control staff to
allow for safe air handling to PE areas and to relocate
immunocompromised patients if necessary

1C

Infection control measures during construction projects
Set up a multidisciplinary team that includes infection control staff
to coordinate proactive preventive measures to reduce exposure
to fungal spores and monitor adherence

1B, 1C

Provide education to HCWs and the construction crew in
immunocompromised patient care areas regarding airborne
infections

1C

Perform an ICRA to assess potential exposure of high-risk patients
to high ambient air fungal spore count

1B, 1C

Develop and implement measures to keep airborne spores from
construction areas away from patient care units
Dust control measures (eg, dust barriers, safe air handling,
negative pressure in construction work zones)
Water damage response plan to prevent fungal growth

1B, 1C

Maintain surveillance for cases of HCF-associated aspergillosis and
mold infections in immunocompromised patients

1B

Undertake an epidemiologic investigation if a case of nosocomial
Aspergillus or other mold infection is detected
Surveillance for additional cases
Determine appropriate air handling in the PE and in construction
areas. Conduct environmental assessment to identify the
source
Take corrective action to improve deficiencies identified and to
eliminate the source of fungal spores

1B

Environmental service recommendations to minimize exposure to fungal spores
Avoid carpeting and upholstered furniture and furnishings in areas
housing immunocompromised patients

1B

(continued on next page)
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Table 3
(continued )
Recommendations

Rating Category

Avoid cleaning methods that disperse dust
Wet dust horizontal surfaces using EPA-registered hospital
disinfectant
Equip vacuums with HEPA filters
Close the doors of rooms of immunocompromised patients when
cleaning
Dry carpeting immediately if wet to prevent growth of fungi,
replace if wet after 72 h

1B

Avoid fresh flowers and potted plants in areas housing
immunocompromised patients

II

Abbreviations: ACH, air changes per hour; EPA, Environmental Protection Agency; HCW, health
care worker; HSCT, hematopoeitic stem cell transplantation; HVAC, heating ventilation air conditioning; 1A, strongly recommended for all hospitals and supported by well-designed experimental
or epidemiologic evidence; 1B, strongly recommended for all hospitals and viewed as effective by
experts because of strong rationale and suggestive evidence; 1C, required by state or federal regulation or representing an established association standard; ICRA, infection control risk assessment;
II, suggested for implementation in many hospitals, supported by suggestive clinical or epidemiologic studies with a strong theoretical rationale or definitive studies applicable to some but not all
hospitals; PE, protected environment.
Data from Sehulster L, Chinn RY. Guidelines for environmental infection control in health-care
facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003;52(RR–10):1–42; and Tablan OC, Anderson LJ, Besser R,
et al. Guidelines for preventing health-care–associated pneumonia, 2003: recommen- dations of
CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep
2004;53(RR–3):1–36.

Infection Control Risk Assessment

Infection control risk assessment is a multistep process that determines the potential
effect of construction within an HCF on the environment and exposure of at-risk patients to infectious agents, particularly fungal spores.69 Implementation of recommended infection control strategies during hospital construction has been successful in
the prevention of fungal contamination of air in patient care areas in prospective environmental surveillance studies using cultures and polymerase chain reaction (PCR)
assays for detection of airborne fungi.70,71 Newer mobile nonfiltration-based air treatment systems that use exposure to electric fields and electrostatic nanofiltration to
destroy airborne organisms have also been effective in preventing fungal contamination during construction.72,73 Additional recommendations for the prevention and control of nosocomial aspergillosis are included in Table 4.

STRATEGIES FOR PREVENTION OF FUNGAL INFECTION IN HEMATOPOIETIC STEM
CELL TRANSPLANTATION RECIPIENTS

To implement strategies to prevent fungal infections in the severely immunocompromised population, it is important to define the high-risk periods. In the allogeneic HSCT
recipient, the risk of infections is related to the time from transplant.15 The post-HSCT
period is generally divided into 3 phases:
 Phase I: the preengraftment period (<30 days after HSCT). Risk of infection is
related to prolonged neutropenia and disruption of the mucocutaneous barriers
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Table 4
Recommendations for prevention and control of healthcare–associated pulmonary
aspergillosis
Recommendations

Rating Category

Staff education
Educate HCWs about infection control procedures to reduce
HCA-PA

II

Surveillance
Conduct surveillance for HCA-PA in severely immunocompromised
patientsa

1A

Monitor for HCA-PA by surveillance and periodic review of
microbiologic and histopathologic data

II

Do not perform routine surveillance cultures of patients or devices

1B

Monitor ventilation status of PE and maintain appropriate standards

1B

Specialized care units for high-risk patients
Provide a PE for care of allogeneic HSCT recipients

1B

Do not routinely use LAF in the PE

1B

No recommendation for a PE for autologous HSCT and SOT
recipients

UR

Minimize the time high-risk patients are outside the PE for
procedures

II

High-risk patients to wear N95 respirators outside the PE
during ongoing construction.
No recommendation for type of mask outside the PE when no
construction
When case of aspergillosis occurs
Assess if health care related or community acquired
Determine if there is an increase in the number of cases of HCA-PA
and IB length of hospital stay

1B

Determine if there is ventilation deficiency in the PE

1B

If not health care related, continue routine maintenance as
mentioned earlier
If health care related, conduct epidemiologic investigation to
identify and eliminate source

1B

Use EPA-registered antifungal biocide for decontamination of
structural materials
Abbreviations: EPA, Environmental Protection Agency; HCA-PA, health care–associated pulmonary
aspergillosis; HCW, health care worker; HSCT, hematopoeitic stem cell transplantation; 1B, strongly
recommended for all hospitals and supported by well-designed experimental or epidemiologic evidence; 1b, strongly recommended for all hospitals and viewed as effective by experts because of
strong rationale and suggestive evidence; II, suggested for implementation in many hospitals, supported by suggestive clinical or epidemiologic studies with a strong theoretical rationale or definitive studies applicable to some but not all hospitals; LAF, laminar airflow; PE, protective
environment; SOT, solid organ transplantation; UR, unresolved, practices for which insufficient evidence or consensus regarding efficacy exists.
a
Severely immunocompromised patients, those with absolute neutrophil counts less than 500/
mm3  2 wk or less than 100/mm3  1 wk, for example, HSCT and SOT recipients and patients on
prolonged high-dose steroids.
Data from Sehulster L, Chinn RY. Guidelines for environmental infection control in health-care
facilities. Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003;52(RR-10):1–42; and Tablan OC, Anderson LJ, Besser R,
et al. Guidelines for preventing health-care–associated pneumonia, 2003: recom- mendations of
CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep
2004;53(RR-3):1–36.
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS
North America) from ClinicalKey.com/nursing by Elsevier on February 14, 2022. For personal use
only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

Nosocomial Fungal Infections

because of cytotoxic chemotherapy. Infections during this period are generally
caused by bacteria, Herpes simplex virus, Candida, and Aspergillus spp.
 Phase II: the postengraftment phase (30–100 days after HSCT). Risk of infection
is related to impaired cell-mediated immunity based on the severity of GVHD and
the intensity of immunosuppressive therapy used for treatment. Infections during
this period are caused by cytomegalovirus (CMV), Aspergillus spp, and P jiroveci.
 Phase III: the late phase (>100 days after HSCT). Risk of infection is dictated by
chronic GVHD and its treatment. Pathogens are primarily CMV, varicella-zoster
virus, encapsulated bacteria, and Aspergillus spp.
As a general measure, avoidance of certain foods has been recommended to
reduce exposure to fungi, primarily during the high-risk period of neutropenia (such
as during receipt of conditioning therapy).15 These foods include unpasteurized dairy
products, cheeses made from mold cultures, uncooked eggs, meat, fish, tofu, unwashed vegetables, and fruits.15
IA displays a bimodal distribution, with increasing number of cases of late-onset disease (>40 days after HSCT) that is associated with immunosuppression for chronic
GVHD.12 A similar pattern of late-onset disease has also been noted with invasive
infection with Zygomycetes and Fusarium58 spp. in HSCT recipients. Educating the
patient in minimizing exposure to Aspergillus spp. and pathogenic molds outside
the hospital is important. However, because the risk of exposure within the hospital
and community settings cannot be eliminated, strategies such as the use of antifungal
prophylaxis may be necessary.
Prevention of Invasive Candidiasis

Antifungal chemoprophylaxis during the preengraftment period of neutropenia and
mucositis can prevent the dissemination of endogenous Candida spp. from the
gastrointestinal tract of patients. The antifungals are outlined in Table 5.
Diagnosis of Invasive Candidiasis

Although BCs are positive in about 50% of patients with IC, they are considered the gold
standard for the diagnosis of candidiasis.3,74 Thus, the true incidence of nosocomial
candidemia is often underestimated. This has resulted in the increasing use of fungal
biomarkers for the detection of candidemia and IC. These assays are used in the clinical
management of patients with suspected IC in situations where BCs may be negative.
However, the use of these assays for routine surveillance of nosocomial IC is yet to
be defined. 1,3 b-D-Glucan (BG) assays and PCR-based assays are some of these tests
used to aid in the diagnosis of IC (Table 6).3 Although b-D glucan has high false-positive
rates and is not specific, it has been shown to have a high negative predictive value in
the ICU setting.3,75 In-house PCR assays are not validated or standardized.3,74
NCT molecular platforms, including fully automated multiplex T2 Magnetic Resonance (T2MR) and T2Candida Panel (T2 Biosystems, Lexington, Massachusetts),74,75
have the potential to improve early diagnosis and management of IC in high-risk patients and outbreak settings. The Food and Drug Administration (FDA)-approved
T2Candida Panel detects the five most common Candida spp. from whole blood by
category: C albicans and/or C tropicalis (A/T); C parapsilosis (P); C krusei, and/or C
glabrata (K/G).75,76
C auris, a nationally reportable pathogen, is difficult to identify and has been often
misidentified as C haemulonii, C famata, C sake, Rhodotorula glutinis, Rhodotorula
mucilaginosa, and Saccharomyces or less commonly as C catenulate, Candida lusitaniae, C guilliermondii, or C parapsilosis or only to the Candida spp. level when using
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Antifungal Agent

Spectrum of Activity

Expected Resistance

Adverse Events

Drug Interactions

Clinical Considerations

Most yeast Dimorphic
fungi
Molds: Aspergillus
fumigatus,
Aspergillus lentulus,
Mucor spp.,
Rhizopus spp.,
Fusarium spp.

Candida lusitaniae,
C guillermondii,
C rugosa,
non-fumigatus
Aspergillus
(Aspergillus
terreus, A. ustus),
Trichosporon spp.,
Scedosporium
apiospermum,
Scedosporium
prolificans

Infusion reactions
(hypoxia, fever,
chills), phlebitis,
nausea, vomiting,
anemia,
nephrotoxicity,
elevated liver
enzymes,
hypersensitivity
reaction

Increased risk of
nephrotoxicity with
other nephrotoxic agents
and hypotension with
blood pressure lowering
agents

Lipid formulations are
associated with less
nephrotoxicity and
infusion reactions

Most yeast, including
most Candida spp.
Dimorphic fungi

Candida krusei
Increasing resistance
in C glabrata
Molds
Dematiaceous fungi

Nausea, vomiting,
diarrhea,
headaches,
hepatitis,
cholestasis and
fulminant hepatitis,
allergic reactions

Inhibits CYP1A2, CYP2C19
CYP2C9, and CYP3A4 and
may increase the
concentration of several
classes of drugs,
including,
anticonvulsants,
antiarrhythmics, steroids,
QT-prolonging agents,
immunosuppressant and
antineoplastic agents,
anticoagulants, ergot
alkaloids, HMG-CoA
reductase inhibitors
(statins)

Dose adjustment required
if GFR is < 50 mL/min
Excellent oral
bioavailability
Highest penetration in CSF
and vitreous among
azoles
High urine concentration
and preferred for cystitis
Step-down therapy in a
critically ill patient who
becomes stable
Alternative initial therapy
in noncritically ill
patients

Polyenes
Conventional and
lipid-based
formulations of
amphotericin B

Triazoles
Fluconazolea
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Table 5
List of antifungal agents used for the prevention and treatment of invasive fungal infections

Yeast, including all
Candida spp.
Mold: most Aspergillus
spp. and Mucor spp.
Dimorphic fungi

Fusarium spp.
Scedosporium
prolificans

Nausea, vomiting,
diarrhea,
abdominal pain,
constipation,
headache, rash,
peripheral edema,
dyspnea, cough,
hepatotoxicity,
hypokalemia
Dose-dependent
QT shortening

Moderate inhibitor of
CYP3A4 and inhibits the
metabolism of sirolimus,
tacrolimus, cyclosporine,
mycophenolate mofetil,
and other drugs
metabolized by CYP3A4

Excellent oral
bioavailability
Large volume of
distribution with long
half-life
Newly approved extended
spectrum triazole for
invasive aspergillosis and
mucormycosis
Use with caution in patients
with severe hepatic
impairment

Itraconazoleb

Most yeast Dimorphic
fungi Molds: most
Aspergillus spp.
Dematiaceous fungi

Candida krusei,
Aspergillus
lentulus,
Aspergillus
terreus,
Fusarium solani,
Rhizopus spp.,
Mucor spp.,
S apiospermum,
S prolificans

Nausea, vomiting,
diarrhea,
abdominal
discomfort,
peripheral and
pulmonary
edema, CHF,
hypertension,
hypokalemia,
hepatotoxicity

Potent CYP3A4 and
P-glycoprotein inhibitor
that increases the
concentration of several
classes of drugs,
including calcium
channel blockers,
antiarrhythmics,
immunosuppressant
agents, anticoagulants,
ergot alkaloids, HMGCoA reductase inhibitors
Contraindicated in patients
with ventricular failure

No IV formulation available
Not well studied for
invasive candidiasis
Primarily used in dimorphic
fungi infections
Therapeutic drug
monitoring required
Use with caution in patients
with liver and renal
failure

Posaconazolea,b

Yeast
Dimorphic fungi
Molds: Aspergillus
spp., F solani,
Mucor spp.,
Rhizopus spp.
Dematiaceous fungi

Scedosporium
prolificans,
S apiospermum

Nausea, vomiting,
diarrhea, fever,
headache,
coughing,
hypokalemia,
and liver enzyme
elevation

Potent CYP3A4 inhibitor
Concomitant use of drugs
that are metabolized
through CYP3A4
(sirolimus, ergot
alkaloids, HMG-CoA
reductase inhibitors) or
CYP3A4 substrates that
prolong the QT interval
(pimozide, quinidine) is
contraindicated

Indicated for
oropharyngeal but
not primary
candidiasis
Primarily used for invasive
Aspergillus and Candida
prophylaxis in high-risk
patients
Oral suspension has
unpredictable
bioavailability
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Antifungal Agent

Spectrum of Activity

Expected Resistance

Adverse Events

Drug Interactions

Clinical Considerations
IV formulation should be
avoided if GFR <50 mL/
min

Voriconazole

Yeast
Dimorphic fungi
molds: most
Aspergillus spp.
Dematiaceous
fungi

Aspergillus lentulus,
Rhizopus spp.,
Mucor spp.

Skin rash,
photosensitivity,
hepatic toxicity,
transient visual
disturbances,
hallucinations,
periostitis,

Inhibits CYP2C19, CYP2C9,
and CYP3A4 and
increases the
concentration of several
classes of drugs,
including steroids,
anticonvulsants,
antiarrhythmics, QTprolonging agents,
immunosuppressant and
antineoplastic agents,
anticoagulants, ergot
alkaloids, HMG-CoA
reductase inhibitors

IV formulation:
cyclodextrin vehicle can
accumulate if GFR
<50 mL/min
Dose adjustment required
in hepatic impairment
Good CSF and vitreous
penetration
Therapeutic drug
monitoring required
First-line therapy for
Aspergillus infections
Step-down oral therapy for
patients with
fluconazole-resistant
Candida spp.

Candida spp.
Aspergillus spp.
Dimorphic fungi

Cryptococcus spp.
Trichosporon spp.
Aspergillus lentulus
Fusarium spp.
S prolificans
Mucor spp.
Dematiaceous fungi

Nausea, vomiting,
diarrhea, fever,
rash, insomnia,
infusion reaction,
edema, elevated
liver enzymes,
hypokalemia,
hypomagnesemia

No major drug interactions

Only available in IV
formulation
Does not penetrate the eye,
CNS, or urine
Fist-line therapy in invasive
candidiasis

Echinocandins
Anidulafungin

Suleyman & Alangaden
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Table 5
(continued )

b

Candida spp.
Aspergillus spp.
Dimorphic fungi

Cryptococcus spp.
Trichosporon spp.
Aspergillus lentulus
Fusarium spp.
S prolificans
Mucor spp.
Dematiaceous fungi

Nausea, vomiting,
diarrhea, headache
edema, chills,
rash, phlebitis,
hypotension,
hypokalemia,
anemia, elevated
liver enzymes

May decrease the serum
concentration of
tacrolimus
Cyclosporine may increase
and rifampin may
decrease the
concentration of
caspofungin

Only available in IV
formulation
Does not penetrate the eye,
CNS, or urine
Dose adjustment in
patients with moderate
hepatic impairment
Fist-line therapy in invasive
candidiasis

Micafungina

Candida spp.
Aspergillus spp.
Dimorphic fungi

Cryptococcus spp.
Trichosporon spp.
Aspergillus lentulus
Fusarium spp.
S prolificans
Mucor spp.
Dematiaceous fungi

Nausea, vomiting,
diarrhea,
abdominal pain,
headache,
insomnia,
phlebitis, skin
reactions,
hepatotoxicity,
hemolytic anemia,
renal failure

Micafungin may increase
the serum concentration
of sirolimus

Only available in IV
formulation
Does not penetrate the eye,
CNS, or urine
Fist-line therapy in invasive
candidiasis

FDA-approved for candidiasis prophylaxis.
FDA-approved for aspergillosis prophylaxis.
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Table 6
Nonculture-based microbiologic tests for detection of invasive fungal infections
Assay

1,3 b-D-Glucan (BG)

Galactomannan (GM)

T2MR Assay

Method

Protease zymogenbased colorimetric
assay

Anti-GM monoclonal
antibody

Amplification and
detection of
Candida DNA by
PCR and T2
magnetic
resonance

Clinical
application

Early detection of IFI

Early detection of
invasive aspergillosis

Early detection of
candidemia
(C albicans,
C glabrata,
C krusei,
C parapsilosis,
C tropicalis

Specimen
type

Serum

Serum, BAL

Whole blood

Result
Interpretation

Negative < 60 pg/mL
Intermediate
60–79 pg/mL
Positive >80 pg/mL

Negative <0.50
Positive >0.50

Negative
Positive
Indeterminate

Sensitivity

67%–84%

BAL: 72%–92%
Serum: 59%–83%

91.1%

Specificity

80%–90%

BAL: 78%–92%
Serum: 92%–94%

99.4%

Cross-reactivity

Pneumocystis jiroveci,
Coccidioides immitis,
Histoplasma
encapsulatum,
Candida spp.,
Acremonium,
Fusarium spp.,
Trichosporon spp.,
Aspergillus spp.

Aspergillus spp.,
Fusarium spp.,
Paecilomyces,
Penicillium spp.,
Alternaria spp.,
Histoplasma
encapsulatum,
Blastomyces
dermatitidis,
Cryptococcus
neoformans

Candida bracarensis,
C metapsilosis,
C orthopsilosis,
Saccharomyces
cerevisiae

False positives

Semisynthetic b-lactam
antibiotics
Hemodialysis with
cellulose membranes,
Bacteremia
Transfusion given
through cellulose
membranes
Gauze
Intravenous
imunoglobulins
and albumin

Semisynthetic b-lactam
antibiotics
Mucositis or GI tract
GVHD
Multiple myeloma
Plasmalyte used in BAL
Cotton swabs

Cross-contamination

(continued on next page)
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Table 6
(continued )
Assay

1,3 b-D-Glucan (BG)

Galactomannan (GM)

T2MR Assay

False negatives

Concomitant use
of antifungals

Concomitant use
of antifungals

Insufficient blood
volume, clotted
blood sample,
specimen not
at room
temperature,
presence of
inhibitors,
technical error,
infection caused
by an organism
not detected by
the panel

standard laboratory methods.8,29,32 If the aforementioned species are identified or
species identity cannot be determined, the CDC recommends further characterization
using alternative methodology, including matrix-assisted laser desorption/ionization
time-of-flight or molecular-based methods. The GenMark ePlex BC Identification
Fungal Pathogen Panel is the first FDA-approved multiplex molecular panel that detects 16 fungal targets, including C auris, from positive BC with a high sensitivity
and specificity.77 The T2Cauris Panel, available for research use, is able to directly
detect several Candida spp. from skin, blood, and environmental samples.78 Various
other PCR methods have been developed for the detection of C auris.
The use of newer NCTs such as T2Candida could impact the reporting of CLABSIs to
NHSN. A positive NCT result may meet the laboratory-confirmed BSI (LCBI) criteria
regardless of the BC result. In response to concerns from reporting health care institutions,
NHSN revised reporting criteria starting January 1, 2020: If an NCT is positive but the BC is
negative 2 days before, the day of, or 1 day after for the same organism, the NCT result is
disregarded. However, if no BC is collected within this timeframe, the NCT result is used for
LCBI surveillance determination and will be reported as a CLABSI if criteria are met.79
Prevention of Aspergillosis

Given the prolonged duration of the risk for aspergillosis in HSCT recipients with
chronic GVHD, guidelines recommend the use of an antimold prophylaxis (see
Table 5).2 The duration of prophylaxis is not clearly defined but is generally dictated
by the severity of GVHD and the intensity of immunosuppression used to treat
GVHD. Antimold prophylaxis has also been recommended for patients with acute myelogenous leukemia and myelodysplastic syndromes during periods of prolonged
neutropenia.2 Among patients receiving SOT, lung transplant recipients are at the
greatest risk for IA. Current guidelines recommend prophylaxis with an antimold azole
agent or inhaled amphotericin B product for 3 to 4 months after lung transplantation.2
Reinitiation of prophylaxis is also recommended after intensification of immunosuppression for episodes of rejection.2 Antimold prophylaxis may be considered in
high-risk patients during institutional outbreaks of mold infection.2
Diagnosis of Invasive Aspergillosis

The true incidence of community-associated or nosocomial IA may be underestimated
as BCs are almost always negative. Diagnosis of invasive pulmonary aspergillosis
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(IPA) has traditionally relied on the isolation of fungi in culture in combination with
compatible histopathologic or radiographic findings. Moreover, it is often difficult to
perform invasive testing in the severely immunocompromised patients to obtain specimens for microbiological testing. This has led to the increasing use of fungal biomarkers for the detection of IA, including the BG and the galactomannan (GM)
assay (see Table 6). These assays are increasingly used in the clinical management
of patients with suspected IA. Serum and bronchoalveolar lavage (BAL) GM and BG
are recommended for the diagnosis of IA in patients with hematologic malignancies
and HSCT recipients. However, GM is not recommended in nonneutropenic patients
given its low sensitivity, and BG is not specific for Aspergillus spp.2 Historically, molecular assays such as PCR were excluded due to lack of standardization and validation. However, recent efforts have been directed at addressing these limitations and
optimizing assay performance using various specimens.80–82 The use of these NCTs
for routine surveillance of nosocomial IA is undefined.
Prevention of Pneumocystis Pneumonia

Pneumocystis pneumonia prophylaxis is recommended for HSCT and SOT recipients
during high-risk periods of immunosuppression, especially the first 100 days after
transplantation.15 Although there is potential for person-to-person transmission of P
jirovecii leading to nosocomial outbreaks, current guidelines do not recommend
specific isolation measures for the care of these hospitalized patients.14 However,
they do recommend avoiding cohorting infected patients with those who are
immunocompromised.14
Diagnosis of Pneumocystis Pneumonia

P jirovecii cannot be cultured, and microscopic visualization of cysts and/or trophozoites in lower respiratory samples (LRSs) such as induced sputum and BAL fluids is the
gold standard for diagnosis, despite the low sensitivity and specificity.82 In recent decades, molecular diagnostics such as PCR are increasingly being used for detection of
P jirovecii in clinical respiratory samples; although the sensitivity (91%–100%) is high,
specificity is much lower (86%) and false-negative results can occur in LRSs.81
Conversely, PCR of oropharyngeal wash fluid has a higher specificity (93%) compared
with LRSs.82 As such, quantitative PCR is preferred to qualitative PCR to establish
probable disease. However, threshold for positivity has not been determined.80
Coronavirus Disease 2019–Associated Candidiasis

Candidemia is increasing reported in critically ill patients with COVID-19, a condition
termed COVID-19–associated candidiasis (CAC).83–86 No specific underlying COVID19–associated immunologic defects that predispose to IC have been identified. The
incidence of CAC ranges from 0.7% to 24% in case series reported from various
geographic regions.83–86 The median time from the hospital or ICU admission to diagnosis of CAC was 10 to 15 days, indicating that CAC is likely an HAI. The overall 30day mortality in patients with CAC was 50% or higher.83,85,86 Non-C albicans species
including C auris were frequently isolated, and infection with non-C albicans spp. was
associated with worse outcomes.83 Potential risk factors included extended ICU stay,
cardiovascular disease (CVD), diabetes mellitus (DM), mechanical ventilation (MV), HD
and prolonged CVC dwell time, and use of tocilizumab.83–86 Traditional risk factors
such as cancer chemotherapy, neutropenia, or transplantation were uncommon.
These reports suggest that CAC predominately results from CVC infection, and the
increased incidence may reflect the unique challenges of caring for critically ill patients
in the ICU during a pandemic. It also highlights the importance of strict adherence to
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infection control measures in ICUs to prevent CLABSIs in critically ill patients with
COVID-19.
CORONAVIRUS DISEASE 2019–ASSOCIATED PULMONARY ASPERGILLOSIS

Critically ill patients with influenza can develop secondary influenza-associated pulmonary aspergillosis.46 Similarly, there have been increasing reports of pulmonary aspergillosis among critically ill patients with COVID-19, a condition termed COVID-19–
associated pulmonary aspergillosis (CAPA).47,87–92 It is believed that CAPA occurs as
a consequence of direct damage to the airway epithelium, impaired immune function
caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and
increased susceptibility to aspergillosis as a result of the use of immune modulatory
therapies such as corticosteroids and IL-6 blockers.92 The incidence of CAPA ranges
from 4.8% to 33% in reports from various geographic locations, among ICU and
non-ICU settings.87–91 The wide range in incidence may be primarily due to the varying
definitions used and the difficulty in establishing the diagnosis as sampling of the lower
respiratory tract was limited due to the risk of aerosolization during bronchoscopy.92 A
recent study from 17 countries, done between March and August 2020, described 186
patients with CAPA defined using established standard criteria.47 The incidence of
CAPA among these patients with COVID-19 ranged from 0.1% to 9.7%, with increasing
incidence of 1.0%–39.1% in patients in the ICU and 1.1%–47.4% in patients requiring
MV.47 In this study, the median time to diagnosis of CAPA was 10 days from diagnosis of
COVID-19 (Interquartile range, IQR: 5–16 days) and 8 days from ICU admission (IQR: 3–
14 days). The time to diagnosis of 7 or more days suggests that most of these cases of
CAPA might be HAIs. CAPA was significantly associated with worse outcomes
compared with patients with COVID-19 without CAPA.88 The overall mortality has
been in excess of 50% with worse outcomes in intubated patients,47,88,89 with CAPA
attributable mortality of 33%.47 Treatment with voriconazole was associated with
improved outcomes.47,89 A fumigatus was the most commonly isolated species, followed by A flavus.47,87–89 Unlike the traditional risk factors of prolonged neutropenia
or transplantation reported with IPA, the underlying comorbidities associated with
CAPA include COVID-19–associated acute respiratory distress syndrome, CVD, renal
failure, DM, chronic lung disease and obesity, and use of cortocosteroids.47,89 Similarly,
the clinical and radiographic features differ from those previously described for IPA. The
diagnosis was established using fungal cultures and NCTs, including BG, GM, aspergillus PCR, and lateral flow assays.91 In order to standardize reporting, consensus
criteria have been proposed for CAPA.91 The diagnosis of CAPA requires entry criteria
of laboratory-confirmed diagnosis of COVID-19 pneumonia in an ICU patient and then
stratifies CAPA as proven, probable, or possible using a combination of histopathology,
clinical features, imaging, and microbiology.
From an infection prevention perspective, the increasing incidence of CAPA in critically ill patients with COVID-19 emphasizes the need for surveillance for nosocomial
aspergillosis in this population and strict adherence to standard measures for mitigating risk for nosocomial aspergillosis as previously described.
SUMMARY

Nosocomial fungal infections, especially IC, including candidemia and IA, can result in
significant morbidity and mortality in critically ill and severely immunocompromised
patients. Implementation of recommended infection control strategies can prevent
catheter-related candidemia and minimize exposure of severely immunocompromised patients to airborne Aspergillus spores within the hospital environment. In select
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patient populations at high risk for invasive fungal infections, antifungal prophylaxis
should be considered during the periods of intense immunosuppression. Newer
nonculture-based methods have the potential to improve the diagnosis of nosocomial
fungal infections.
CLINICS CARE POINTS
 Surveillance for new entities of COVID-19–associated invasive candidiasis and aspergillosis
and emerging fungal pathogen C auris is important.
 Thoughtful application of newer nonculture-based fungal diagnostics can improve
identification of nosocomial infections.
 Adherence to established infection prevention and control practices is essential to minimize
risk of nosocomial fungal infections.
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